Clinical Trials Logo

Acute Myeloid Leukemia clinical trials

View clinical trials related to Acute Myeloid Leukemia.

Filter by:

NCT ID: NCT03560882 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

Start date: August 1, 2018
Phase: Phase 1
Study type: Interventional

This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of conformational mutant tumor protein 53 (p53) in malignant diseases (solid tumor and relapsed Acute Myeloid Leukemia (AML)).

NCT ID: NCT03555955 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

Start date: July 2018
Phase: Phase 1
Study type: Interventional

This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.

NCT ID: NCT03552029 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

DS-3032b Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Start date: June 2018
Phase: Phase 1
Study type: Interventional

Participants with AML that has gone into remission and come back (relapsed) or gone into remission with a number of leukemia cells still in their system (refractory) will be recruited for this study. They will also have a biomarker called FLT3 in their blood. Participants will receive a combined dose of quizartinib and another experimental drug that has not been approved by the US Food and Drug Administration yet (m). The combination of these drugs will be provided in different amounts on defined days (dosing schedules). It is expected that the combination of quizartinib and DS-3032b will be safe and well tolerated. It is expected that the combination may fight the leukemia better than a single drug. The study will run for approximately 3 years. There may be up to 156 participants. The study has 2 parts: - Part 1 will test approximately 24-36 participants in 10 study centers in the United States. Participants will receive two study drugs (DS-3032b and quizartinib) in different amounts on specific days. Information will be gathered to see what dosing schedule of the drug combination is best (maximum tolerated/recommended dose). - Part 2 of the study will confirm the recommended dosing schedule identified in Part 1 is effective. A larger number of participants will receive the recommended dose in up to an additional 15 sites worldwide as necessary, based on the enrollment rate, the population, and the standard of care available to them at the time.

NCT ID: NCT03537560 Enrolling by invitation - Clinical trials for Acute Myeloid Leukemia

Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML

Start date: March 1, 2017
Phase:
Study type: Observational

1. Detection of IDH2 mutations in AML patients to define it incidence and correlation with clinical characteristics, relapse-free and overall survival. 2. Identify AML patients who are potential candidates for IDH2 inhibitor treatment. 3. Monitoring minimal residual disease (MRD) following therapy to evaluate its possible role in the strategy of MRD-directed therapy in the future in patients carrying IDH2 mutations at initial diagnosis.

NCT ID: NCT03533816 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Start date: August 2018
Phase: Phase 1
Study type: Interventional

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).

NCT ID: NCT03531918 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm

Start date: July 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dosing frequency of gemtuzumab ozogamicin when given in combination with granulocyte colony stimulating factor (G-CSF), cladribine, cytarabine and mitoxantrone (GCLAM) and to see how well they work in treating participants with acute myeloid leukemia or high-grade myeloid tumors (neoplasms) that have not been previously treated. Antibody-drug conjugates, such as gemtuzumab ozogamicin, act by directly delivering toxic chemotherapy to cancer cells. Granulocyte colony stimulating factor is a growth factor used to stimulate leukemia cells and render them more sensitive to chemotherapy drugs. Drugs used in chemotherapy, such as cladribine, cytarabine and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving gemtuzumab ozogamicin in combination with G-CSF, cladribine, cytarabine and mitoxantrone hydrochloride may work better in treating participants with acute myeloid leukemia or high-grade myeloid neoplasm.

NCT ID: NCT03530085 Recruiting - Clinical trials for Acute Myeloid Leukemia

Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT

Start date: May 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is reported to be able to improve the outcomes for elderly acute myeloid leukemia (AML) in complete remission (CR). At present, the best conditioning regimen for elderly AML in CR remains in discussion. In this prospective study, the safety and efficacy of Dec+Flu+Bu myeloablative conditioning regimens in patients with elderly AML in CR undergoing allo-HSCT are evaluated.

NCT ID: NCT03526666 Recruiting - Clinical trials for Acute Myeloid Leukemia

Ascorbic Acid Levels in MDS, AML, and CMML Patients

Start date: November 1, 2017
Phase:
Study type: Observational

This study is a non-interventional, specimen collection translational study to evaluate vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.

NCT ID: NCT03516760 Recruiting - Clinical trials for Acute Myeloid Leukemia

Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia

Start date: April 11, 2018
Phase: Phase 1
Study type: Interventional

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML). This AML was relapsed after previous therapy or was refractory to the standard therapy.

NCT ID: NCT03515707 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

Start date: June 15, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well autologous stem cell transplant works in treating patients with favorable or intermediate risk, minimal residual disease (MRD)-negative, acute myeloid leukemia. Giving chemotherapy before a peripheral blood stem cell transplant helps kill any cancer cells that are in the body. After treatment, stem cells are collected from the patient's blood and stored. Higher dose chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.